QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: jpet.104.068320v1 311/1/204    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Clozel, M. Articles by Ziltener, P. Search for Related Content PubMed PubMed Citation Articles by Clozel, M. Articles by Ziltener, P.

CARDIOVASCULAR

Pharmacology of the Urotensin-II Receptor Antagonist Palosuran (ACT-058362; 1-[2-(4-Benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea Sulfate Salt): First Demonstration of a Pathophysiological Role of the Urotensin System

Actelion Pharmaceuticals Ltd., Innovation Centre, Allschwil, Switzerland

Urotensin-II (U-II) is a cyclic peptide now described as the most potent vasoconstrictor known. U-II binds to a specific G protein-coupled receptor, formerly the orphan receptor GPR14, now renamed urotensin receptor (UT receptor), and present in mammalian species. Palosuran (ACT-058362; 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea sulfate salt) is a new potent and specific antagonist of the human UT receptor. ACT-058362 antagonizes the specific binding of ¹²⁵I-labeled U-II on natural and recombinant cells carrying the human UT receptor with a high affinity in the low nanomolar range and a competitive mode of antagonism, revealed only with prolonged incubation times. ACT-058362 also inhibits U-II-induced calcium mobilization and mitogen-activated protein kinase phosphorylation. The binding inhibitory potency of ACT-058362 is more than 100-fold less on the rat than on the human UT receptor, which is reflected in a pD'₂ value of 5.2 for inhibiting contraction of isolated rat aortic rings induced by U-II. In functional assays of short incubation times, ACT-058362 behaves as an apparent noncompetitive inhibitor. In vivo, intravenous ACT-058362 prevents the no-reflow phenomenon, which follows renal artery clamping in rats, without decreasing blood pressure and prevents the subsequent development of acute renal failure and the histological consequences of ischemia. In conclusion, the in vivo efficacy of the specific UT receptor antagonist ACT-058362 reveals a role of endogenous U-II in renal ischemia. As a selective renal vasodilator, ACT-058362 may be effective in other renal diseases.

Address correspondence to: Dr. Martine Clozel, Actelion Pharmaceuticals Ltd., Innovation Centre, Gewerbestrasse 16, Allschwil, CH-4123, Switzerland. E-mail: martine.clozel{at}actelion.com

This article has been cited by other articles:

				P. N. Sidharta, P. L. M. van Giersbergen, and J. Dingemanse Pharmacokinetics and Pharmacodynamics of the Urotensin-II Receptor Antagonist Palosuran in Healthy Male Subjects J. Clin. Pharmacol., October 1, 2009; 49(10): 1168 - 1175. [Abstract] [Full Text] [PDF]

				L. Giuliani, L. Lenzini, M. Antonello, E. Aldighieri, A. S. Belloni, A. Fassina, C. Gomez-Sanchez, and G. P. Rossi Expression and Functional Role of Urotensin-II and Its Receptor in the Adrenal Cortex and Medulla: Novel Insights for the Pathophysiology of Primary Aldosteronism J. Clin. Endocrinol. Metab., February 1, 2009; 94(2): 684 - 690. [Abstract] [Full Text] [PDF]

				L. Tian, C. Li, J. Qi, P. Fu, X. Yu, X. Li, and L. Cai Diabetes-induced upregulation of urotensin II and its receptor plays an important role in TGF-{beta}1-mediated renal fibrosis and dysfunction Am J Physiol Endocrinol Metab, November 1, 2008; 295(5): E1234 - E1242. [Abstract] [Full Text] [PDF]

				D. Ribatti, M. T. Conconi, and G. G. Nussdorfer Nonclassic Endogenous Novel Regulators of Angiogenesis Pharmacol. Rev., June 1, 2007; 59(2): 185 - 205. [Abstract] [Full Text] [PDF]

				E. Ovcharenko, Z. Abassi, I. Rubinstein, A. Kaballa, A. Hoffman, and J. Winaver Renal effects of human urotensin-II in rats with experimental congestive heart failure Nephrol. Dial. Transplant., May 1, 2006; 21(5): 1205 - 1211. [Abstract] [Full Text] [PDF]

				M. Clozel, P. Hess, C. Qiu, S.-S. Ding, and M. Rey The Urotensin-II Receptor Antagonist Palosuran Improves Pancreatic and Renal Function in Diabetic Rats J. Pharmacol. Exp. Ther., March 1, 2006; 316(3): 1115 - 1121. [Abstract] [Full Text] [PDF]

				G. Giebing, M. Tolle, J. Jurgensen, J. Eichhorst, J. Furkert, M. Beyermann, F. Neuschafer-Rube, W. Rosenthal, W. Zidek, M. van der Giet, et al. Arrestin-Independent Internalization and Recycling of the Urotensin Receptor Contribute to Long-Lasting Urotensin II-Mediated Vasoconstriction Circ. Res., September 30, 2005; 97(7): 707 - 715. [Abstract] [Full Text] [PDF]